Today, July 14, 2026, marks a pivotal moment for Celcuity Inc. (NASDAQ: CELC) and for thousands of breast cancer patients, as the U.S. Food and Drug Administration (FDA) granted approval for REVTORPYK™ (gedatolisib). This decision, announced ahead of the anticipated July 17 Prescription Drug User Fee Act (PDUFA) goal date, greenlights REVTORPYK for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer without a PIK3CA mutation, following progression on or after at least one line of endocrine therapy in the metastatic setting.
The news sent Celcuity shares soaring during regular trading hours, closing up 6.99% at $111.05, pushing the company's market capitalization to $5.42 billion. However, the initial euphoria tempered slightly in after-hours trading, with the stock pulling back to $104.95, a 5.5% decline from its closing price. This immediate volatility underscores the high expectations that have surrounded Celcuity, which has seen its stock price surge by 677% over the past six months in anticipation of this regulatory milestone. The approval of REVTORPYK represents not just a scientific achievement but a potential commercial inflection point for the Minneapolis-based biotechnology firm.
REVTORPYK's approval is underpinned by compelling data from the Phase 3 VIKTORIA-1 trial, which evaluated gedatolisib in combination with palbociclib and fulvestrant (triplet) or with fulvestrant alone (doublet) in patients with PIK3CA wild-type advanced or metastatic breast cancer. The results demonstrated a substantial reduction in the risk of disease progression or death, highlighting REVTORPYK's potent anti-tumor activity.
| Regimen | Risk Reduction (vs. Fulvestrant) | Median Progression-Free Survival (PFS) | Objective Response Rate (ORR) |
|---|---|---|---|
| REVTORPYK + Palbociclib + Fulvestrant | 76% | 11.1 months | 48.9% |
| REVTORPYK + Fulvestrant | 67% | 11.3 months | 35.7% |
| Piqray + Fulvestrant (comparative arm) | N/A | 5.6 months | N/A |
Source: Celcuity Inc. clinical trial data
Notably, the gedatolisib doublet achieved a median progression-free survival (PFS) of 11.3 months, significantly outperforming Novartis’ PI3K inhibitor Piqray (alpelisib) combined with fulvestrant, which yielded a median PFS of just 5.6 months in a comparative arm. This nearly doubled PFS for REVTORPYK underscores its potential to become a new standard of care for this patient population. Celcuity projects an addressable market of $5 billion to $6 billion in the U.S. alone for this indication, with peak revenue potential estimated at $2.5 billion to $3 billion. Looking further out, analysts forecast Celcuity to reach significant revenue milestones, with consensus estimates projecting revenue to hit $0.7 billion by fiscal year 2028 and $1.0 billion by fiscal year 2029.
The scientific community has long recognized the PI3K/AKT/mTOR (PAM) pathway as a critical driver of cancer cell growth, yet comprehensively inhibiting it has proven elusive for decades. Brian Sullivan, CEO and co-founder of Celcuity, articulated this challenge, stating, "The PI3K/AKT/mTOR, or PAM, pathway is one of the most important targets in cancer, but comprehensively inhibiting it has stymied researchers and drug developers for nearly two decades." He further emphasized REVTORPYK's breakthrough, noting, "REVTORPYK addressed this 20-year challenge by becoming the first pan-PI3K, mTORC1/2 inhibitor approved by the FDA."
REVTORPYK's mechanism of action is distinct, as it is the only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2. This comprehensive blockade of the PAM pathway differentiates it from existing single-node inhibitors like alpelisib (PI3Kα inhibitor), capivasertib (AKT inhibitor), and everolimus (mTORC1 inhibitor), which have shown limited efficacy due to adaptive resistance mechanisms. Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity, highlighted the clinical impact, stating, "Today's approval of REVTORPYK addresses a significant unmet need for the thousands of patients affected each year by HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer whose disease has progressed after endocrine therapy."
Beyond its efficacy, REVTORPYK also boasts a favorable safety profile. Administered as an intravenous infusion three times a month, its less frequent dosing schedule compared to daily oral medicines is a key advantage. Sullivan noted, "We report nominal hyperglycemia lower than has ever been reported for drugs in this class," addressing a common side effect of PAM pathway inhibitors. While neutropenia (a drop in white blood cells) and stomatitis (mouth inflammation) were the most significant adverse events, the overall tolerability profile, as described by Dr. Gorbatchevsky, "compares very favorably to those from the patient group treated with alpelisib and fulvestrant."
With FDA approval secured, Celcuity is now poised for commercial launch, which it anticipates in late Q3 2026. The company has already designed a comprehensive patient support program to ensure broad and affordable access to REVTORPYK, including an expanded access program for eligible patients prior to full commercial availability. This strategic focus on patient access reflects Celcuity's commitment to maximizing the drug's reach in the market.
Looking beyond the initial indication, Celcuity plans to submit a supplemental New Drug Application (sNDA) to the FDA in Q3 2026 for REVTORPYK for the treatment of HR+/HER2-, PIK3CA mutant breast cancer patients. This move aims to expand the drug's label to a broader patient population. The company is also actively developing gedatolisib for other indications, including first-line treatment of HR+/HER2- locally advanced or metastatic breast cancer and metastatic castration-resistant prostate cancer, with ongoing Phase 3 trials. CEO Brian Sullivan expressed ambitious long-term goals, stating that if gedatolisib proves effective in these "frontline efforts," it could set Celcuity on a path to becoming a $10 billion company, tapping into a "big $20 billion tent" in the frontline population. The company has been scaling up its operations, growing its employee base from 55 at the end of 2023 to 155 by the end of 2024 and 2025, reflecting its preparation for commercialization. Furthermore, a public offering of 0.250% Convertible Senior Notes due 2032 in June 2026 provided additional capital to support these growth initiatives.
While the FDA approval of REVTORPYK is a monumental achievement, Celcuity faces significant challenges, particularly in managing market expectations and executing a successful commercial launch. The stock's impressive 677% rally over the past six months, driven by anticipation of this approval, suggests that a substantial portion of the good news may already be priced in. The after-hours dip of 5.5% following the official announcement, despite the positive news, hints at the market's "buy the rumor, sell the news" dynamic and the high bar set for Celcuity.
A key point of tension emerged from the ASCO 2026 presentation, where REVTORPYK's median PFS results of 11.3 months (doublet) and 11.1 months (triplet) were reported. While these figures represent a significant improvement over Piqray, they came in slightly below the more optimistic expectations of some analysts. Leerink Partners, for instance, had anticipated a PFS of around 12 months for the doublet and between 14 and 15 months for the triplet. This gap between analyst forecasts and reported data, though small, could influence investor sentiment and create headwinds if commercial uptake doesn't meet aggressive projections.
Moreover, the commercialization of a new oncology drug is a complex undertaking. Despite REVTORPYK's differentiated mechanism and efficacy, Celcuity will need to effectively compete with established therapies and navigate the intricacies of market access, reimbursement, and physician adoption. The current valuation, with analysts projecting a P/E ratio of around 53.4x on 2029 earnings, significantly higher than the U.S. Biotechnology industry average of 21.2x, reflects a substantial growth premium. Any missteps in commercial execution or slower-than-expected revenue ramp-up could lead to a re-evaluation of this premium.
Despite the inherent risks of a commercial-stage biotech, Wall Street analysts maintain a largely bullish outlook on Celcuity. The consensus analyst rating for CELC is a "Buy," with 8 out of 9 analysts tracked by Kavout giving it a Buy rating and only 1 recommending a Hold. This strong sentiment is further supported by a median price target of $116.00, with a high target of $155.00 and a low of $77.00.
Recent analyst actions reinforce this positive trend. Needham, for instance, maintained its "Buy" rating on March 10, 2026, following a previous upgrade of its price target from $95 to $122. Jefferies also maintained a "Buy" rating on December 2, 2025, increasing its price target from $108 to $134. From the current price of $111.05, the median price target of $116.00 implies a modest 4.46% upside, suggesting that much of the near-term upside from the approval has already been factored in. However, the highest individual price target of $155.00 still represents a potential 39.58% upside, indicating that some analysts see substantial room for growth as commercialization unfolds.
The FDA approval of REVTORPYK is a watershed moment for Celcuity, transforming it from a clinical-stage biotech into a commercial entity with a first-in-class, multi-billion dollar drug. The early approval, coupled with REVTORPYK's superior efficacy and favorable safety profile in HR+/HER2- breast cancer, validates years of research and positions the company for significant revenue generation. While the stock's substantial run-up and the slight after-hours pullback indicate that high expectations are already baked into the price, the long-term growth trajectory, driven by label expansion and pipeline development, remains compelling. Investors should recognize the inherent volatility in biotech but consider the transformative potential of this approval.
For investors looking to participate in Celcuity's new chapter, an entry zone between $100 and $105 per share would offer a more attractive risk-reward profile, accounting for the immediate post-approval volatility. Our 12-month target price for CELC is $135.00, reflecting successful commercialization and progress on pipeline expansion. An invalidation level below $90.00 would suggest a fundamental shift in the commercial outlook or competitive landscape, warranting a re-evaluation of the investment thesis. Celcuity has successfully navigated the regulatory gauntlet; now, the focus shifts to executing its commercial vision and delivering on its multi-billion dollar promise.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
